Delving into the Latest Updates on Amikacin/Cefepime with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Potentox

Target

30S subunit x PBPs

Mechanism

30S subunit inhibitors(30S ribosomal subunit inhibitors), PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesRespiratory Diseases

Active Indication

Febrile NeutropeniaHealthcare-Associated Pneumonia

Inactive Indication-

Originator Organization

Venus Remedies Ltd.

Active Organization

Venus Remedies Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H24N6O5S2

InChIKeyHVFLCNVBZFFHBT-ZKDACBOMSA-N

CAS Registry88040-23-7

View All Structures (2)

The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung disease.
The first part of the study is the 84-day double-blind phase to evaluate the primary and secondary endpoints.

Start Date19 Apr 2012

Sponsor / Collaborator

Insmed, Inc.

[+1]

100 Clinical Results associated with Amikacin/Cefepime

Login to view more data

100 Translational Medicine associated with Amikacin/Cefepime

Login to view more data

100 Patents (Medical) associated with Amikacin/Cefepime

Login to view more data

2

Literatures (Medical) associated with Amikacin/Cefepime

01 Jan 2009·Experimental Lung ResearchQ4 · MEDICINE

FIXED-DOSE COMBINATION OF CEFEPIME PLUS AMIKACIN (POTENTOX) INHIBITS PNEUMONIA INFECTION

Q4 · MEDICINE

Article

Author: Soni A ; Dwivedi Vk ; Chaudhary M ; Shrivastava Sm ; Singh Cp

Pneumonia is a severe infection that causes high morbidity and mortality rate worldwide. It is caused by Klebsiella pneumoniae, which generally causes upper respiratory tract infection. In case of such type of infection, levels of oxidant and antioxidant become imbalanced, which may contribute to lung injury. The present study was planned to evaluate the status of oxidant and antioxidant enzyme activities in plasma and lung tissue of pneumonia-infected rats model. Animals were randomly distributed into 3 groups of 8 rats each: groups I (control, normal saline treated), II (infected group), and III (infected + treated group). The findings showed that there was significant increase (P < .001) in body temperature along with decreased body weight in the infected group as compared to the control group. Similarly, all the activities of antioxidant enzymes (superoxide dismutase [SOD], catalase) were significantly decreased along with increased malonaldialdehyde (MDA) levels in plasma and lung tissue of the infected group as compared to the control group. These enzyme activities along with MDA levels were improved and came back near to normal level after administration of cefepime plus amikacin (potentox) for 7 days in group III. These studies concluded that fixed-dose combination of potentox improved oxidant and antioxidant levels in pneumonia infection.

01 Sep 2008·Current Clinical Pharmacology

Fixed Dose Combination of Cefepime Plus Amikacin Prevent Oxidative Stress in Liver of Mus musculus Mice

Article

Author: Soni, Arvind ; Chaudhary, Manu ; Dwivedi, Vivek Kumar

Oxidative stress and free radical are causative factors for aminoglycoside induced tissue injury. The objective of present study was to evaluate effect of fixed dose combination of cefepime + amikacin on antioxidant enzymes such as superoxide dismutase (SOD), catalase along with malonaldialdehyde (MDA) levels in liver of Mus musculus mice. Our findings showed that the activities of the antioxidant enzymes such as superoxide dismutase (p<0.001, 62.2%), catalase (p<0.05, 47.5%) were significantly lowered along with increase in the MDA levels (66.0%) after the single treatment of amikacin as compared to control group. A significant improvement in the activities of superoxide dismutase and catalase along with decrease in MDA levels were observed in fixed dose combination of cefepime plus amikacin treated groups as compared to amikacin alone treated group. These findings suggest that the fixed dose combination therapy of cefepime + amikacin (Potentox) show significant free radical scavenging property which may contribute to decrease in aminoglycoside induced liver injury.

100 Deals associated with Amikacin/Cefepime

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J01RA06	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Febrile Neutropenia	-	Venus Remedies Ltd.	-
Healthcare-Associated Pneumonia	-	Venus Remedies Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01315236 (CTgov)	Phase 2	Mycobacterium Infections, Nontuberculous	90	Liposomal amikacin for inhalation (LAI) (LAI 590 mg QD)	xsqlvvungl(huscwkrlpr) = xfymqvuxkl sbjwrkyqao (gfcrpbrjja, tvktxvssxm - rgfevozolz) View more	-	21 Aug 2019
				placebo (Placebo)	xsqlvvungl(huscwkrlpr) = qyctqekero sbjwrkyqao (gfcrpbrjja, lskpdeixin - tlbruskdip) View more